SMARCA4

Across TCGA pan-cancer cohorts, SMARCA4 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated SMARCA4 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SMARCA4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SMARCA4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, LIHC, and LUAD are the cancer types where SMARCA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.963	0.819	.001	36	view →
LIHC	OS	Median	All	0.157	0.679	<.001	21	view →
LUAD	DFS	Median	All	0.446	0.678	<.001	21	view →
STAD	DFS	Median	II,III,IV	1.000	0.470	.025	18	view →
SKCM	OS	Median	II,III,IV	0.945	0.713	.005	14	view →
ESCA	DFS	Median	III,IV	1.000	0.382	.025	13	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
READ	DFS	Median	IV	0.082	0.619	.001	6	view →
PRAD	DFS	Median	All	0.166	0.888	<.001	6	view →
SCLC	OS	Median	II,III,IV	1.000	0.369	.014	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

SMARCA4–UCEC (DFS)

Open the UCEC breakdown →